| 000 | 01882 a2200565 4500 | ||
|---|---|---|---|
| 005 | 20250514035745.0 | ||
| 264 | 0 | _c20030711 | |
| 008 | 200307s 0 0 eng d | ||
| 022 | _a0268-3369 | ||
| 024 | 7 |
_a10.1038/sj.bmt.1703602 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCohen, A D | |
| 245 | 0 | 0 |
_aGemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease. _h[electronic resource] |
| 260 |
_bBone marrow transplantation _cJul 2002 |
||
| 300 |
_a23-8 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAcute Disease |
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAminoglycosides |
| 650 | 0 | 4 |
_aAnti-Bacterial Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadministration & dosage |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 | _aCause of Death |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGemtuzumab |
| 650 | 0 | 4 | _aHematopoietic Stem Cell Transplantation |
| 650 | 0 | 4 |
_aHepatic Veno-Occlusive Disease _xchemically induced |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunotoxins _xadministration & dosage |
| 650 | 0 | 4 | _aIncidence |
| 650 | 0 | 4 |
_aLeukemia, Myeloid _xcomplications |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aSalvage Therapy |
| 650 | 0 | 4 | _aTherapeutic Equivalency |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aLuger, S M | |
| 700 | 1 | _aSickles, C | |
| 700 | 1 | _aMangan, P A | |
| 700 | 1 | _aPorter, D L | |
| 700 | 1 | _aSchuster, S J | |
| 700 | 1 | _aTsai, D E | |
| 700 | 1 | _aNasta, S | |
| 700 | 1 | _aGewirtz, A M | |
| 700 | 1 | _aStadtmauer, E A | |
| 773 | 0 |
_tBone marrow transplantation _gvol. 30 _gno. 1 _gp. 23-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/sj.bmt.1703602 _zAvailable from publisher's website |
| 999 |
_c11997237 _d11997237 |
||